Cynata Therapeutics

Cynata Therapeutics Limited (ASX: CYP) is a clinical-stage stem cell and regenerative medicine company. Cynata is focussed on the development and commercialisation of a proprietary induced pluripotent stem cell (iPSC)-based platform technology, Cymerus™.

Mesenchymal stem cells (also known as mesenchymal stromal cells or MSCs) have huge therapeutic potential for numerous unmet medical needs. However, it is challenging to manufacture MSCs consistently and at scale using conventional methods.

The Cymerus™ platform utilises iPSC technology to enable scalable manufacture of MSC-based products for human therapeutic use. The primary advantage of the Cymerus™ platform is its ability to produce an effectively limitless number of consistent, high quality MSCs from a single cell bank, which in turn was derived from a single donation, from a single donor donor. This avoids challenges associated with conventional MSC manufacturing methods, including the need for new tissue donations from different donors on an ongoing basis, which is associated with substantial variability and potential impacts on MSC functionality. 

Learn more about Cymerus™ here, and how Cynata is set to accelerate the commercialisation of MSC therapies worldwide.